Himalayan Re IPO Survives Court Challenge, but Ruling Raises Barrier for Future Premium Issues

Kathmandu — Himalayan Reinsurance has avoided the cancellation of its controversial premium-priced initial public offering, but the Supreme Court’s ruling may prove far more consequential for Nepal’s insurance and capital markets than the dismissal of the case itself.

The court dismissed the writ petition seeking to overturn Himalayan Re’s IPO after concluding that the share issuance, allotment and transfer to investors had already been completed. Reversing the transaction at such an advanced stage was therefore not considered appropriate.

But the dismissal should not be read as judicial approval of the way the premium IPO was authorised.

In its full judgment, the Supreme Court questioned the legal basis used by the Nepal Insurance Authority and the Securities Board of Nepal (SEBON) to permit Himalayan Reinsurance to sell shares to the public above their face value.

The court interpreted Section 45(5) of the Insurance Act, 2079 as restricting insurance companies from collecting more than the face value of shares sold to the general public.

That interpretation is likely to have implications well beyond Himalayan Re.

Company keeps IPO, regulators face questions

The immediate outcome favours existing Himalayan Re shareholders.

The company’s IPO will not be cancelled, shares already allotted to investors remain valid and the completed transaction will not be reversed.

But the broader legal finding goes in a different direction.

The judgment indicates that the regulators should not have treated general provisions governing premium share issuance as sufficient without first examining the restrictions contained in the Insurance Act.

The court treated the Insurance Act as the specific legislation governing insurance companies. In legal interpretation, a specific law governing a particular sector generally carries greater weight on that subject than a broader general provision.

That distinction lies at the centre of the case.

Himalayan Reinsurance, SEBON and the Insurance Authority had argued that the share issue complied with the Companies Act, securities legislation and the Securities Registration and Issue Regulations.

The petitioners, however, argued that an insurance company was also bound by the more specific restriction contained in the Insurance Act.

The Supreme Court’s interpretation substantially supports that legal argument, even though it did not grant the petitioners their requested remedy of cancelling the IPO.

Rs 3.18 billion premium at the centre of dispute

The financial scale of the disputed transaction was significant.

Himalayan Reinsurance issued 30 million shares at Rs 206 each. Each share carried a face value of Rs 100 and a premium of Rs 106.

At that price, the total issue was worth approximately Rs 6.18 billion.

Of that amount, around Rs 3 billion represented the face value of the shares, while approximately Rs 3.18 billion came from the premium charged above par value.

The premium component was therefore slightly larger than the face-value capital raised through the offering.

Put differently, investors paid Rs 206 for every Rs 100 of nominal share capital they received.

That explains why the interpretation of whether an insurance company could legally collect a premium was not a minor procedural question. It concerned billions of rupees collected from public investors.

Why did the court not cancel the IPO?

The apparent contradiction in the ruling is that the court questioned the legality of the approval process but still dismissed the petition challenging the IPO.

The explanation lies largely in the stage the transaction had reached.

By the time the case was finally decided, Himalayan Reinsurance had already completed the public offering. Shares had been allotted and investors had acquired ownership.

Cancelling such a transaction after completion could have created a chain of additional legal and financial problems involving the company, shareholders, securities records and potentially subsequent market transactions.

The joint bench of Justices Shrikanta Paudel and Manoj Kumar Sharma therefore concluded that the specific relief demanded by the petitioners could no longer practically be granted.

The decision effectively separates two questions.

The first was whether the completed Himalayan Re IPO should now be cancelled. The court’s answer was no.

The second was whether similar premium issues by insurance companies should be approved under the same interpretation of the law in the future. On that question, the judgment sends a much more restrictive message.

SEBON’s approval process under scrutiny

The ruling is particularly significant for SEBON because the securities regulator is responsible for examining public offerings before investors are allowed to subscribe.

The court observed that the board should have adequately examined both the prospectus and the applicable legal provisions before approving the offering.

That finding raises a larger regulatory issue.

Approval of an IPO is not merely an administrative exercise in checking whether forms, financial statements and procedural documents have been submitted. Regulators are also expected to determine whether the proposed transaction is permitted under the laws governing the issuing company.

In Himalayan Re’s case, the court’s reasoning suggests that compliance with securities regulations alone was insufficient.

Because the issuer was an insurance company, SEBON also needed to consider the restrictions imposed by insurance legislation.

The ruling could therefore force greater legal scrutiny of future public offerings involving heavily regulated industries.

Insurance Authority also questioned

The Nepal Insurance Authority faces a similar issue.

As the sector regulator, the authority is expected to ensure that insurers comply with the Insurance Act before giving regulatory consent or making recommendations connected with capital raising.

The court questioned why the authority recommended or permitted the premium issuance despite the wording of Section 45(5).

This is important because companies operating in regulated sectors frequently require approvals from more than one institution.

The Himalayan Re case shows the risk created when one regulator focuses on sectoral compliance while another concentrates on securities rules without a sufficiently coordinated interpretation of the law.

The judgment effectively places greater responsibility on both regulators to ensure that their approvals are compatible rather than merely procedurally complete.

Premium money will not simply disappear

The court has also addressed the treatment of the premium already collected.

Rather than directing Himalayan Reinsurance to refund the premium to investors, the court instructed the Insurance Authority, SEBON and the company to coordinate in ensuring that the premium amount is maintained in the appropriate reserve or share-premium fund in accordance with the Companies Act, 2063 and the Insurance Act, 2079.

That distinction matters.

The approximately Rs 3.18 billion collected as premium is not being treated as ordinary revenue that the company can use without restriction.

Share premium is generally treated separately from normal operating income and is subject to legal rules governing how such funds may be maintained or utilised.

The directive therefore seeks to protect the financial character of the money already collected while avoiding the disruption that would result from unwinding the IPO.

Future insurance IPOs could face a different route

The biggest impact of the judgment may emerge when another insurance company seeks to issue shares at a premium.

Until now, an insurer might have relied on provisions under company and securities laws allowing qualifying companies to issue shares above face value.

The Supreme Court’s interpretation complicates that route.

If Section 45(5) of the Insurance Act is applied as the court has interpreted it, an insurance company cannot simply rely on general premium-share provisions to charge public investors more than face value.

That could effectively restrict future premium IPOs by insurers unless the governing law is amended, clarified or otherwise provides a specific legal basis.

The implications extend to both life and non-life insurers considering capital raising from the public.

Companies preparing an IPO will now have to examine not merely whether they satisfy SEBON’s financial criteria for premium issuance, but whether the insurance law permits the pricing structure in the first place.

A warning for regulators, not a punishment for investors

The judgment appears designed to avoid making existing investors bear the consequences of regulatory shortcomings.

Investors subscribed to the Himalayan Re IPO after approvals had been granted by the relevant authorities. They did not determine the legal interpretation used by SEBON or the Insurance Authority.

Cancelling the shares after allotment could therefore have imposed losses and uncertainty on investors who relied on official regulatory approvals.

By leaving the completed transaction intact while issuing directions for the future, the court has placed responsibility primarily on regulatory institutions rather than on investors who participated in the offering.

That approach also reduces the risk of destabilising securities already issued and traded.

A broader question of regulatory accountability

The case raises questions extending beyond one reinsurance company.

Nepal’s capital market depends heavily on investors believing that securities approved by regulators have undergone adequate legal and financial scrutiny.

When courts later conclude that an approval process did not sufficiently comply with the governing law, confidence in regulatory screening can be weakened.

That is why the Supreme Court’s criticism of SEBON and the Insurance Authority may ultimately be more important than the dismissal of the writ itself.

The decision signals that regulators cannot rely only on their own sector-specific rules when approving complex financial transactions. They must examine the complete legal framework governing the institution seeking approval.

For investors, that means regulatory approval should ideally represent more than permission to sell securities. It should also provide reasonable assurance that the structure of the offering has been examined against all applicable laws.

The verdict has two very different consequences

For Himalayan Reinsurance, the immediate consequence is relatively straightforward: its IPO survives.

For Nepal’s insurance industry, however, the consequences are potentially much larger.

The ruling creates a significant interpretive benchmark for future premium IPOs, strengthens the importance of the Insurance Act in determining how insurers may raise public capital and puts greater pressure on SEBON and the Insurance Authority to coordinate their decisions.

The case therefore ends with an unusual split outcome.

The petitioners failed to have Himalayan Re’s completed IPO cancelled, but the legal argument at the heart of their challenge has shaped the rules that regulators will now have to consider in future offerings.

In that sense, Himalayan Re keeps the benefit of a transaction already completed, while the door through which that transaction was approved may have become considerably narrower for the next insurance company seeking to follow the same path.